Over recent years antihypertensive drugs, particularly angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), have been reported to have beneficial effects upon cognitive impairment. Such findings suggest that pharmacological manipulation of angiotensin ligands may be of clinical importance in slowing or halting the cognitive deterioration seen in vascular dementia and Alzheimer's disease.The mechanism(s) underlying these improvements in cognitive function remains unclear; however, important leads are emerging. The angiotensin AT 4 receptor subtype, discovered by our laboratory in 1992, influences several important behaviours and physiologies, including learning and memory, and may play a role in this cognitive improvement.This review initially describes the therapeutic drugs approved by the Federal Drug Administration and new approaches presently being developed to treat Alzheimer's disease-induced cognitive impairment. Next, the biologically-active angiotensin ligands and their respective receptor subtypes are discussed, followed by the roles of angiotensin II, angiotensin IV, ACE inhibitors and ARBs in cognitive function.We conclude with a working hypothesis concerning the importance of the AT4 receptor subtype as a new potential drug target for the treatment of Alzheimer's disease-associated memory loss.
Small GW, Rabins PV, Barry PP et al. Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA1997;278:1363-71.
2.
Clark CMClinical manifestations and diagnostic evalulation of patients with Alzheimer's disease. In: Clark CM and Trajanowski JQ (eds.). Neurodegenerative Dementias: Clinical Features and Pathological Mechanisms. New York : McGraw-Hill, 2000;95-114.
3.
Zec RF, Trivedi MAThe effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol Rev2002 ;12:65-109.
4.
Doody R., Dunn J., Clark CM et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord2001;12:295-330.
5.
Salloway S., Ferris S., Kluger A. et al. Efficacy of donepezil in mild cognitive impairment: a randomized, placebo-controlled trial. Neurology2004;63:651-7.
6.
Petersen RC, Thomas RG, Grundman M. et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med2005;352:2379-88.
7.
Doraiswamy M. , Xiong GLPharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother2006;7:1-10.
8.
Topper R., Gehrmann J., Banati R. et al. Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain inury. Acta Neuropathol1995;89:23-8.
9.
Seif EI, Nasr M., Peruche B. et al. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol1990;185:19-24.
10.
Miguel-Hidalgo JI, Alvarex XA, Cacabelos R., Quack G.Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res2002;958:210-21.
Jourdi H., Yanagihara T., Martinez U. et al. Effects of positive AMPA receptor modulators on calpain-mediated spectrin degradation in cultured hippocampal slices. Neurochem Int2005;46:31-40.
13.
Francis PTGlutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer's disease. Neurodegener Dis2008 ;5:241-3.
14.
Bliss TV, Gerner-Medwin ARLong-lasting potentiation of synaptic transmission in the dentate area of the unanesthetized rabbit following stimulation of the perforant path . J Physiol1973;232:357-74.
15.
Bliss TV, Lomo T.Long-term potentiation of synaptic transmission in the dentate area of the anesthetized rabbit following stimulation of the perforant path. J Physiol1973; 232:331-56.
16.
Lynch G., Rex CS, Gall CMLTP consolidation: substrates, explanatory power, and functional significance . Neuropharmacology2007;52:12-23.
17.
Wright JW, Yamamoto BJ, Harding JWAngiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets. Prog Neurobiol2008;84:157-81.
18.
Malenka RC, Bear MFLTP and LTD: an embarrassment of riches. Neuron2004;44:5-21.
19.
Wezenberg E. , Verkes RJ, Ruigt GS et al. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology2007;32:1272-83.
20.
McGeer PL, McGeer EGInflammation, autotoxicity and Alzheimer's disease. Neurobiol Aging2001;22:799-809.
21.
Leuchtenberger S., Maler J., Czirr E. et al. Nonsteroidal anti-inflammatory drugs and ectodomain shedding of the amyloid precursor protein . Neurodegener Dis2008;(In press).
22.
Sainati SM, Ingram DM, Talwalker S. et al. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. 6th International Stockholm/Springfield Meeting on Advances in Alzheimer Therapy, 5-8 April 2000, Stockholm , Sweden.
23.
Aisen PS, Schafer KA, Grundman M. et al. Effects of rofecoxib or naproxen versus placebo on Alzheimer's disease progression. JAMA2003;289:2819-26.
24.
Winblad B., Palmer K., Kivipelto M. et al. Mild cognitive impairment - beyond controversies, toward a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med2004;256:240-6.
25.
Ezoulin MJ, Liu Z., Dutertere-Catella H. et al. A new acetylcholinesterase inhibitor with anti-PAF activity modulates oxidative stress and pro-inflammatory mediators release in stimulated RAW 264.7 macrophage cells. Comparison with tacrine. Int Immunopharmacol2007;7:1685-94.
26.
Sparks DL, Martin TA, Gross DR et al. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech2000;50:287-90.
27.
de la Torre JCVascular basis of Alzheimer's pathogenesis . Ann N Y Acad Sci2002;977:196-215.
28.
de la Torre JCHow do heart disease and stroke become risk factors for Alzheimer's disease?Neurol Res2006;28:637-44.
29.
Benedict RHCognitive function after open-heart surgery: are postoperative neuropsychological deficits caused by cardiopulmonary bypass?Neuropsychol Rev1994;4:223-55.
30.
Brown WR, Moody DM, Tytell M. et al. Microembolic brain injuries from cardiac surgery: are they seeds of future Alzheimer's disease?Ann N Y Acad Sci1997;826:386-9.
31.
Caplan I.Protecting the brains of patients after heart surgery. Arch Neurol2001;58:549-50.
32.
Raja PV, Blumenthal JA, Doraiswamy PMCognitive deficits following coronary artery bypass grafting: prevalence, prognosis, and therapeutic strategies. CNS Spectr2004;9:763-72.
33.
Forette F., Seux MI, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Sys-Eur) study. Arch Intern Med2002;162:2046-52.
34.
The PROGRESS Collaborative Group.Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease . Arch Intern Med2003;163:1069-75.
35.
Fox NC, Black RS, Gilman S. et al. Effects of A immunization (AN1792) on MRI measures of cerebral volume in Alzheimer's disease. Neurology2005 ;64:1563-72.
36.
Oken BS, Storzbach DM, Kaye JAThe efficacy of ginkgo biloba on cognitive function in Alzheimer's disease . Arch Neurol1998;55:1409-15.
37.
Wettstein A.Cholinesterase inhibitors and ginkgo extracts: are they comparable in the treatment of dementia?Phytomedicine2000;6:393-401.
38.
Van Dongen MV, Rossum EV, Kessels A. et al. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol2003;56:367-76.
39.
Burns NR, Bryan J., Nettelbeck T.Ginkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults. Hum Psychopharmacol2006;21:27-37.
40.
Birks J., Grimley Evans J., Lee H.Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev2007;18:CD003120.
41.
Bae CY, Cho CY, Cho K. et al. A double-blind, placebo-controlled, multicenter study of cerebrolysin for Alzheimer's disease. J Am Geriatr Soc2000;48:1566-71.
42.
Rüther E., Ritter R., Apecechea M. et al. Sustained improvement in patients with dementia of Alzheimer's type (DAT) 6 months after termination of cerebrolysin therapy. J Neural Transm2002;107:815-29.
43.
Lonn E., Bosch J., Yusuf S. et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA2005;293:1338-47.
44.
Johnston CIBiochemistry and pharmacology of the renin-angiotensin system. Drugs1990;39:21-31.
45.
Vauquelin G. , Michotte Y., Smolders I. et al. Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. J Renin Angiotensin Aldosterone Syst2002;3:195-204.
46.
Speth RC, Brown TE, Barnes RD, Wright JWBrain angiotensinergic activity: the state of our current knowledge . Proc West Pharmacol Soc2003;46:11-15.
47.
Stragier B. , Bundel DD, Sarre S. et al. Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review . Heart Fail Rev2008;13:321-37.
48.
de Gasparo M., Catt KJ, Inagami T. et al. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev2000;52:415-72.
49.
Ferrario CMRole of angiotensin II in cardiovascular disease - therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst2006;7:3-14.
50.
Glossmann H. , Baukal A., Catt KJAngiotensin II receptors in bovine adrenal cortex. Modification of angiotensin II binding by guanyl nucleotides. J Biol Chem1974;249:664-6.
51.
Bennett JP Jr, Snyder SHAngiotensin II binding to mammalian brain membranes. J Biol Chem1976;251:7423-30.
52.
Harding JW, Cook VI, Miller-Wing AV et al. Identification of an AII (3-8) AIV binding site in guinea pig hippocampus. Brain Res1992;583:340-3.
53.
Swanson GN, Hanesworth JM, Sardinia MF et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept1992;40:409-19.
54.
Jarvis MF, Gessner GW, Ly CGThe angiotensin hexapeptide 3-8 fragment potently inhibits [125I] angiotensin II binding to non-AT1 or -AT2 recognition sites in bovine adrenal cortex. Eur J Pharmacol1992;19:319-22.
55.
Bernier SG, Fournier A., Guillemette G.A specific binding site recognizing a fragment of angiotensin II in bovine adrenal cortex membranes. Eur J Pharmacol1994;271:55-63.
Mustafa T., Lee JH, Chai SY et al. Bioactive angiotensin peptides: focus on angiotensin IV. J Renin Angiotensin Aldosterone Syst2001;2:205-10.
58.
Ferrario CMContribution of angiotensin-(1-7) to cardiovascular physiology and pathology. Curr Hypertens Rep2003;5:129-34.
59.
Neves LA, Averill DB, Ferrario CM et al. Characterization of angiotensin-(1-7) receptor subtype in mesenteric arteries. Peptides2003;24:455-62.
60.
Wright JW, Krámar EA, Meighan SE, Harding JWExtracellular matrix molecules, long-term potentiation, memory consolidation and the brain angiotensin system. Peptides2002;23:221-46.
61.
Wright JW, Harding JWThe brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory. Prog Neurobiol2004;72:263-93.
62.
Wright JW, Harding JWImportant roles for angiotensin III and IV in the brain renin-angiotensin system. Brain Res Rev1997;25:96-124.
63.
Kehoe PG, Wilcock GKIs inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?Lancet Neurol2007 ;6:373-8.
64.
Kramkowski K., Mogielnicki A., Buczko W.The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol2006;4:529-39.
65.
Ellul J., Archer N., Foy CM et al. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry2006;78:233-9.
66.
Croog SH, Levine S., Testa MA et al. The effects of antihypertensive therapy on the quality of life . N Engl J Med1986;314:1657-74.
67.
Deicken RFCaptopril treatment of depression. Biol Psychiatry1986;12:1425-8.
68.
Zubenko GS, Nixon RAMood-elevating effect of captopril in depressed patients. Am J Psychiatry1984;141:110-11.
69.
Barnes JM, Barnes NM, Costall B. et al. Angiotensin-converting enzyme inhibition, angiotensin, and cognition . J Cardiovasc Pharmacol1992;19(suppl 6):S63-S71.
70.
Bartus RT, Dean RL, Beer B., Lippa ASThe cholinergic hypothesis of geriatric memory dysfunction. Science1982;217: 408-17.
71.
Barnes NM, Champaneria S., Costall B. et al. Cognitive enhancing actions of DuP 753 detected in a mouse habituation paradigm. Neuroreport1990;1:239-42.
72.
Costall B., Coughlan J., Horovitz ZP et al. The effects of ACE inhibitors captopril and SQ29852 in rodent tests of cognition. Pharmacol Biochem Behav1989;33:573-9.
73.
Morris RGDevelopment of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods1984;11:47-60.
74.
Barnes NM, Cheng CH, Costall B. et al. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol1991;20: 289-92.
75.
Barnes NM, Costall B., Egli P. et al. Characterization of [3H]ceranapril recognition sites in rat and human brain tissue. Neuropharmacology1991 ;30:907-14.
76.
Barnes JM, Barnes NM, Costall B. et al. ACE inhibition and cognition. In: MacGregor GA and Sever PS (eds.). Current Advances in ACE Inhibition. New York: Churchill Livingston Press, 1989;159-71.
77.
Mondadori C. , Etienne P.Nootropic effects of ACE inhibitors in mice . Psychopharmacology1990;100:301-07.
78.
Flood JF, Morley JEDose-response differences in the ability of ramipril to improve retention in diabetic mice. Eur J Pharmacol1993;240:311-14.
79.
Barnes NM, Costall B., Kelly ME et al. Cognitive enhancing actions of PD123177 detected in a mouse habituation paradigm. Neuroreport1991;2:351-3.
80.
DeNoble VJ, DeNoble KF, Spencer KR et al. Non-peptide angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor: effect on a renin-induced deficit of a passive avoidance response in rats. Brain Res1991;561:230-5.
81.
Chen BZ, Mendelsohn FAO.Effect of acute and chronic administration of ceranapril on angiotensin converting enzyme in plasma, kidney, lung, brain regions and cerebrospinal fluid of rats . Neuropharmacology1992;31:929-35.
82.
Manschot SM , Biessels GJ, Cameron NE et al. Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats . Brain Res2003;966:274-82.
83.
Wyss JM, Kadish I., van Groen T.Age-related decline in spatial learning and memory: attenuation by captopril . Clin Exp Hypertens2003;25:455-74.
84.
Jenkins TA, Chai SYEffect of chronic angiotensin converting enzyme inhibition on spatial memory and anxiety-like behaviours in rats. Neurobiol Learn Mem2007;87:218-24.
85.
Amenta F., Di Tullio MA, Tomassoni D.The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin Exp Hypertens2002;24:697-713.
86.
The PROGRESS Collaborative Group.Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack . Lancet2001;358:1033-41.
87.
Rozzini L., Chilovi BV, Vertoletti E. et al. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry2006;21:550-5.
88.
Poon IOEffects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy2008;28:366-75.
89.
Hajjar IM, Keown M., Lewis P., Almor A.Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study. Am J Alzheimers Dis Other Demen2008;23:77-83.
90.
Hu J., Igarashi A., Kamata M., Nakagawa H.Angiotensin converting enzyme degrades Alzheimer amyloid beta-peptide (A beta): retards A beta aggregation, deposition, fibril formation, and inhibits cytotoxicity . J Biol Chem2001;276:47863-8.
91.
Oba R., Igarashi A., Kamata M. et al. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci2005;21:733-40.
92.
Hemming ML, Selkoe DJAmyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem2005;280:37644-50.
93.
Kehoe PG, Russ C., McIlory S. et al. Variation in DCP1 encoding ACE is associated with susceptibility to Alzheimer disease. Nat Genet1999;21:71-2.
94.
Kehoe PGThe renin-angiotensin-aldosterone system and Alzheimer's disease?J Renin Angiotensin Aldosterone Syst2003 ;4:80-93.
95.
Kehoe PG, Katzov H., Feuk L. et al. Haplotypes extending across ACE are associated with Alzheimer's disease. Hum Mol Genet2003;12:859-67.
96.
Wright JW, Harding JWAngiotensins in brain function. In: Lim R (ed.). Handbook of Neurochemistry and Molecular Neurobiology: Neuroactive Proteins and Peptides. New York: Springer Science Publications, 2006;627-53.
97.
Carson JA, Turner AJBeta-amyloid catabolism: roles for heprilysin (NEP) and other metallopeptidases?J Neurochem2002;81:1-8.
98.
Gard PRAngiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets2004 ;8:7-14.
99.
Lee J, Chai SY, Mendelsohn FA et al. Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology 2001;40:618-23. 100. Gard PR, Rusted M. Angiotensin and Alzheimer's disease: therapeutic prospects. Expert Rev Neurother 2004;4:87-96.
100.
Tedesco MA , Ratti G., Mennella S. et al. Comparison of losartan and hydroclorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens1999;12:1130-4.
101.
Fogari R., Preti P., Mugellini A. et al. Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients. Am J Hypertens2002;15:36A.
102.
Hansson L. , Lithell H., Skoog I. et al. Cognition and prognosis in the elderly (SCOPE). Blood Press1999;8:177-83.
103.
Trenkwalder P.The Study on COgnition and Prognosis in the Elderly (SCOPE) - recent analyses. J Hypertens2006;24(suppl 1):S107-14.
104.
Zanchetti A., Elmfeldt D.Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review. Blood Press2006;15:71-9.
105.
Birkenhäger WH, Staessen JAProgress in cardiovascular diseases: cognitive function in essential hypertension. Prog Cardiovasc Dis2006;49:1-10.
106.
Hanes DS, Weir MRUsefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. Am J Geriatr Cardiol2007;16:175-82.
107.
Wang JM, Boudhuin P., Courtoy PJ, de Potter WPConversion of angiotensin II into active fragments by an endosomal pathway in bovine adrenal medullary cells in primary culture. Endocrinology1995;136:5274-82.
108.
Gáborik Z. , Szaszák M., Szidonya L. et al. -arrestin and dynamin-dependent endocytosis of the AT1 angiotensin receptor. Mol Pharmacol2001;59:239-47.
109.
Dale JB, Seachrist JL, Banwah AV et al. Regulation of angiotensin II type 1A receptor intracellular retention, degradation, and recycling by Rab5, Rab7, and Rab11 GTPases. J Biol Chem2004;279:13110-18.
110.
Kramár EA, Armstrong DL, Ikeda S. et al. The effects of angiotensin IV on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Res2001;897:114-21.
111.
Wayner MJ, Armstrong DL, Phelix CF et al. Angiotensin IV enhances LTP in rat dentate gyrus in vivo. Peptides2001;22:1403-14.
112.
Wayner MJ, Polan-Curtain JL, Armstrong DLDose and time dependency of angiotensin II inhibition of hippocampal long-term potentiation. Peptides1995;16:1079-82.
113.
Davis CJ, Kramar EA, De A. et al. AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation . Neuroscience2006;137:1369-79.
114.
Braszko JJ , Kupryszewski G., Witczuk B., Wisniewski K.Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and conditioned avoidance responses in rats. Neuroscience1988;27:777-83.
115.
Braszko JJ , Wlasienko J., Koziolkiewicz W. et al. The 3-7 fragment of angiotensin II is probably responsible for its psychoactive properties . Brain Res1991;542:49-54.
116.
Wright JW, Miller-Wing AV, Shaffer MJ et al. Angiotensin II(3-8) [ANG IV] hippocampal binding: potential role in the facilitation of memory. Brain Res Bull1993;32:497-502.
117.
Wright JW, Krebs LT, Stobb JW, Harding JWThe angiotensin IV system: functional implications. Front Neuroendocrinol1995;16:23-52.
118.
Wright JW, Stubley L., Pederson ES et al. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci1999 ;19:3952-61.
119.
Stubley-Weatherly LA, Harding JW, Wright JW. Effects of discrete kainic acid-induced hippocampal lesions on spatial and contextual learning and memory. Brain Res 1996;716:29-38. 121. Pederson ES, Harding JW, Wright JW. Attenuation of scopolamine-induced spatial learning impairments by an angioensin IV analog. Regul Pept 1998;74:97-103.
120.
Pederson ES , Krishnan R., Harding JW, Wright JWA role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. Regul Pept2001;102:147-56.
121.
Olson ML, Olson EA, Qualls JH et al. Norleucine1angiotensin IV alleviates mecamylamine-induced spatial memory deficits. Peptides2004;25:233-41.
122.
Roberts KA , Krebs LT, Kramár EA et al. Autoradiographic identification of brain angiotensin IV binding sites and differential c-fos expression following intracerebroventricular injection of angiotensin II and IV in rats. Brain Res1995;682:13-21.
123.
Zhu B. , Herbert J.Central antagonism of atrial natriuretic peptides on behavioral and hormonal responses to angiotensin II: mapping with c-fos . Brain Res1996;734:55-60.
124.
Lee J. , Albiston AL, Allen AM et al. Effect of icv injection of AT4 receptor ligands, Nle1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats . Neuroscience2004;24:341-9.
125.
Albiston AL , Peck GR, Yeatman HR et al. Therapeutic targeting of insulin-regulation aminopeptidase: head and tails?Pharmacol Ther2007;116:417-27.
126.
Chai SY, Fernando R., Peck G. et al. The angiotensin IV/AT4 receptor. Cell Mol Life Sci2004;61:2728-37.
127.
Wright JW, Harding JWBrain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions . Regul Pept1995;59:269-95.
128.
Basso N., Paglia N., Stella I.Protective effect of the inhibition of the renin-angiotensin system on aging . Regul Pept2005;128:247-52.
129.
Hajjar IM, Keown M., Frost B.Antihypertensive agents for aging patients who are at risk for cognitive dysfunction . Curr Hypertens Rep2005;7:466-73.
130.
Khachaturian AS, Zandi PP, Lyketsos CG et al. Antihypertensive medication use and incident Alzheimer disease. Arch Neurol2006 ;63:686-92.
131.
Braszko JJ , Walesiuk A., Wielgat P.Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV. J Renin Angiotensin Aldosterone Syst2006;7:168-74.
132.
Chai SY, Bastias MA, Clune EF et al. Distribution of angiotensin IV binding sites (AT4 receptor) in the human forebrain, midbrain and pons as visualized by in vitro receptor autoradiography. J Chem Neuroanat2000;20:339-48.
133.
Gard PRThe role of angiotensin II in cognition and behaviour. Eur J Pharmacol2002;438:1-14.
134.
Meighan SE , Meighan PC, Choudhury P. et al. Effects of extracellular matrix-degrading proteases matrixmetalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J Neurochem2006;96:1227-41.
135.
Meighan PC , Meighan SE, Davis CJ et al. Effects of matrix metalloproteinase inhibition on short- and long-term plasticity of schaffer collateral/CA1 synapses . J Neurochem2007 ;102:2085-96.
136.
Stragier B., Sarre S., Vanderheyden P. et al. Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat. J Neurochem2004;90:1251-7.
137.
Lee J., Mustafa T., McDowall SG et al. Structure-activity study of LVV-hemorphin-7: angiotensin AT4 receptor ligand and inhibitor of insulin-regulated aminopeptidase. J Pharmacol Exp Ther2003;305:205-11.
138.
Andersson H., Demaegdt H., Vauquelin G. et al. Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Bioorg Med Chem2008;16:6924-35.
